Tinnitus Therapies: Neurodegenerative Treatment Insights

Tinnitus is not just a phantom sound. According to a systematic review by researchers J L Liu and Peng Liu, it is a neurological condition with deep biological roots shared with diseases like Alzheimer’s and Parkinson’s. The authors argue that tinnitus involves maladaptive neuroplasticity—harmful rewiring of the brain—within both auditory and non-auditory brain networks. This rewiring process mirrors the neuroinflammation, synaptic dysfunction, and excitotoxicity seen in neurodegenerative disorders. Their work, published in Frontiers in Aging Neuroscience, suggests a direct path for treating tinnitus: repurpose drugs and strategies already in development for those brain diseases.

Shared Mechanisms: Neuroinflammation and Excitotoxicity

The central premise of the review is that tinnitus and neurodegeneration are driven by similar pathological engines. One major engine is neuroinflammation. In neurodegenerative diseases, chronic inflammation in the brain damages neurons. In tinnitus, similar inflammatory cascades are activated in the auditory pathways, potentially stabilizing the faulty neural circuits that generate the phantom sound.

Another key shared mechanism is glutamate-mediated excitotoxicity. Glutamate is the brain’s primary excitatory chemical messenger. When its regulation fails, neurons can become overstimulated and die. This process is a hallmark of neurodegeneration. In tinnitus, excessive glutamate activity in auditory centers like the cochlear nucleus and inferior colliculus is thought to hypersensitize neurons, contributing to both the perception and persistence of the ringing or buzzing sound.

This mechanistic overlap is more than theoretical. It provides a clear rationale for borrowing therapeutic approaches. As the authors state, “targeting neuroinflammatory cascades, modulating neurotrophic factors, and mitigating glutamate-mediated excitotoxicity” are strategies with proven potential in neurodegeneration research and could be applied to tinnitus.

Preclinical Evidence Supports Drug Repurposing

Liu and Liu systematically examined evidence from animal and cellular models of tinnitus. They found that drugs designed to interfere with neurodegenerative processes can also affect tinnitus-related pathways.

For example, anti-inflammatory agents like minocycline or compounds that inhibit specific pro-inflammatory cytokines have shown promise in reducing tinnitus-like behavior in animals. Drugs that modulate neurotrophic factors—proteins that support neuron survival and health—could help repair dysfunctional auditory synapses. Perhaps most directly, medications that block excessive glutamate activity, such as certain NMDA receptor antagonists, have demonstrated efficacy in reducing neuronal hyperactivity in tinnitus models.

This preclinical evidence is compelling because it moves beyond merely suppressing the symptom. It attacks the proposed biological underpinnings: the inflammatory milieu, the loss of synaptic integrity, and the excitotoxic environment that sustains the maladaptive neural network.

The Clinical Translation Landscape

While the theoretical framework and preclinical data are strong, the review notes that clinical translation for tinnitus remains in its early stages. Few of these repurposed strategies have undergone large-scale, controlled human trials specifically for tinnitus.

Some existing tinnitus treatments already indirectly touch on these mechanisms. For instance, certain neuromodulation approaches aim to correct “aberrant neural network reorganization,” a process the review highlights. Techniques like Coordinated Reset Therapy directly target pathological brain rhythms, which may be related to the broader concept of thalamocortical dysrhythmia discussed in conditions like chronic pain and tinnitus.

The challenge now is to deliberately test neurodegenerative disease therapeutics in well-designed tinnitus trials. This requires a shift from generic sound therapy or counseling to mechanism-based intervention. The review by Liu and Liu provides the necessary biological roadmap for that shift.

Practical Implications for Future Treatment

For patients and clinicians, this research signals a potential future direction. Tinnitus management may evolve to include pharmacological options that target its core neurobiology, similar to how multiple sclerosis or Alzheimer’s disease is treated.

This approach could be particularly relevant for cases of tinnitus linked to sudden hearing loss, where acute neural damage and inflammation are likely contributors. A drug that combats neuroinflammation or excitotoxicity at the time of hearing loss might prevent tinnitus from establishing itself.

It also reinforces the understanding that tinnitus is a whole-brain condition, not just an ear problem. Non-auditory pathways involving memory, emotion, and attention are involved in its persistence. Treatments that protect or repair neural networks broadly, as many neurodegenerative drugs aim to do, could therefore have a significant impact.

The review by Liu and Liu synthesizes a compelling argument: tinnitus treatment can learn from the fight against neurodegeneration. By focusing on shared root causes—neuroinflammation, excitotoxicity, and synaptic failure—researchers can develop more effective interventions. The evidence from preclinical studies is promising, and the next critical step is rigorous clinical testing. This work moves the field closer to treatments that address the biology of tinnitus, not just its perception.

Source: Liu JL, Liu P. (2026). Repurposing Neurodegenerative Disease Therapeutic Strategies for Tinnitus Intervention: A Systematic Review. Frontiers in Aging Neuroscience. DOI: 10.3389/fnagi.2026.1835649.